Register now to R3i !
Your Login
Your Password
Confirm Password  
Your Email
MSDA 2017 REGISTER AND SUBMIT YOUR ABSTRACT ONLINE NOW!
Online registration and abstract submission is now open for the 12th Metabolic Syndrome, Type 2 Diabetes and Atherosclerosis Congress (MSDA 2017), St. Petersburg, Russia, 8-10 June, 2017.
 
Register here for attendance to all scientific sessions and exhibit area, program and abstract
For information on group registration please refer to the MSDA Congress website :
REGISTRATION
 
Submit your abstract now! Abstracts should be prepared in English language and submitted to the MSDA Scientific Committee;
full details are provided here:
ABSTRACT SUBMISSION
Register Now - Don’t miss out!
Be a part of this premier event focused at the cross roads of cardiology,
diabetology and lipidology!
R3i editorial
24 April 2017

Prof. Jean Charles Fruchart, Prof. Michel Hermans, Prof. Pierre Amarenco
Residual cardiovascular risk in the Middle East: a perfect storm in the makingRead more...

Continuing our theme of residual cardiovascular risk in developing regions we turn our attention to countries in the Middle East and North Africa (MENA), a region in critical health flux.
Already in 2010, ischaemic heart disease was the leading cause of death and disability in the region, driven by the dual epidemics of type 2 diabetes and obesity. Data from the International Federation of Diabetes show that more than 35 million people living in the MENA region have diabetes and this number is expected to double by 2040. One in 10 adults has diabetes, half of them undiagnosed ...
PCSK9 and Atherosclerosis
Downloadable slidekit
PCSK9 downloadable slidekit
Created by Professors Jean Davignon (Vice-President of the R3i foundation), Jean-Charles Fruchart (President of R3i) and Michel Hermans (R3i General Secretary), the latest downloadable deck of 242 slides discusses the potential role for anti-PCSK9 mAbs in the future management of cardiovascular disease.
landmark study
24 April 2017

ACCORDION: Does fenofibrate have a legacy effect in lipid-related residual cardiovascular risk in type 2 diabetes? Read more...

The ACCORD Lipid trial did not show a significant effect on cardiovascular risk associated with fenofibrate treatment in type 2 diabetes patients on simvastatin therapy, although there was evidence of potential benefit in patients with atherogenic dyslipidaemia at baseline (1). It has been argued that...
focus on...
24 April 2017

High mortality risk in ischaemic stroke patients in Arab countriesRead more...

Stroke is important contributor to cardiovascular morbidity and mortality. In developing regions, such as the Middle East and North Africa, projected rates of death due to stroke are anticipated to double by 2030 (1). The current report also shows that among individuals with a history...
recent publication

Is inflammation a key determinant of the atherogenicity of remnant cholesterol?Read more...

Attention has refocused on remnant cholesterol, transported by triglyceride-enriched precursors...
recent publication

Pemafibrate (K-877) add-on to statin: More trials reportRead more...

Two new trials add to evidence of robust reduction in...
recent publication

Do peroxisome proliferator-activated receptor targeted treatments have a role in fatty liver disease?Read more...

Non-alcoholic fatty liver disease (NAFLD) encompasses the spectrum of diseases...
recent publication

HDL-cholesterol and triglycerides linked with insulin secretion in non-diabetic individualsRead more...

Although experimental studies suggest that lipoproteins directly affect beta cell...
recent publication

Gender disparity in lipid targets for men and women in the Arabian GulfRead more...

Women living in the Arabian Gulf, especially those at very...

What is residual risk ?

Residual risk of vascular events persisting in patients at treatment goals according to current standards of care or failing to meet goals, including risk related to dyslipidemia, high blood pressure, hyperglycemia, systemic inflammation and unhealthy lifestyles.

What is the Initiative ?

The R3i, a worldwide, academic, multidisciplinary non-profit organization, aims to successfully address the excessively high risk of macro- and micro-vascular complications in patients with atherogenic dyslipidemia, characterised by elevated triglycerides and low levels of high-density lipoprotein (HDL) cholesterol and unaddressed by current standards of care.